Authors

Latest:

Dr Ma on Interim Efficacy and Safety Data With RLY-2608 in PI3Kα-Mutant HR+/HER2– Breast Cancer

Cynthia X. Ma, MD, PhD, discusses positive interim data from the phase 1 ReDiscover trial in PI3Kα-mutated HR-positive, HER2-negative breast cancer.

Cynthia Sears, MD

Latest:

Dr. Sears on Ongoing Research of Microbiota in CRC

Cynthia L. Sears, MD, professor of Medicine, at Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses ongoing research of microbiota for patients with colorectal cancer (CRC).

Cynthia Yoshida, MD

Latest:

UVA Screening Program Seeks to Get Ahead of Colorectal Cancer

Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.

Cyrus M. Khan, MD

Cyrus M. Khan, MD, is an assistant professor of medicine at the Drexel University School of Medicine and assistant director of the Stem Cell Transplant Program at the Allegheny Health Network Cancer Institute in Pittsburgh, Pennsylvania.

Latest:

Dr Khan on the Evolution of BTK Inhibitors in CLL

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

Ross Camidge, MD, PhD

D. Ross Camidge, MD, PhD, is a professor of medicine-medical oncology, and director of the Thoracic Oncology Clinical Program and Clinical Research Program at the University of Colorado Cancer Center – Anschutz Medical Campus.

Latest:

How Compelling Communication Makes Early Cancer Detection Part of Everyday Life: With D. Ross Camidge, MD, PhD; and Keith Singer

Camidge and Singer discuss how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness.

D. Ross Camidge, MD, PhD, University of Colorado

Latest:

Dr. Camidge on Toxicities of Sunvozertinib in EGFR Exon 20–Mutated NSCLC

Ross Camidge, MD, PhD, discusses toxicities observed with sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer.

D. Ross Camidge, MD, University of Colorado Cancer Center

D. Ross Camidge, MD, University of Colorado School of Medicine

Dale Chenoweth

Latest:

Immune Checkpoint Inhibitors Hold Promise In Glioblastoma

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

Dale R. Shepard, MD, PhD, FACP, Taussig Cancer Institute, Cleveland Clinic

Damian Laber, MD

Latest:

Dr. Laber on the PRODIGE 35-PANOPTIMOX Trial in Metastatic Pancreatic Cancer

Damian Laber, MD, hematologist/oncologist, senior member, Moffitt Cancer Center, discusses the PRODIGE 35-PANOPTIMOX trial in metastatic pancreatic cancer.

Damon Reed, MD, Moffitt Cancer Center

Latest:

Dr Reed on the Investigation of Trastuzumab Deruxtecan in HER2+ Osteosarcoma

Damon R. Reed, MD, discusses a phase 2 study of fam-trastuzumab deruxtecan-nxki in adolescent and young adult patients with recurrent HER2-positive osteosarcoma.

Dan Beachler,MD

Latest:

Dr. Beachler on HPV Vaccine Efficacy Among Previously Exposed Individuals

Dan Beachler, MD, fellow at the National Cancer Institute, discusses the efficacy of the HPV vaccine on individuals who have been previously exposed to the virus compared to those who have not.

Latest:

Specialty Pharmacy: Build, Buy, or Partner

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dan George, MD, Duke Cancer Center

Latest:

Advanced Prostate Cancer: Remaining Challenges

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Daniel J. George, MD, Duke Cancer Institute

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment